# Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiot

Source: https://onco.cc/trials/nct07001618/  
OnCo record `nct07001618` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of cemiplimab, cisplatin, pemetrexed, bevacizumab and other drugs in lung cancer, run by Gustave Roussy, Cancer Campus, Grand Paris, now recruiting.

## Summary

Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung Cancer is a phase 2, randomised interventional study registered as NCT07001618 by Gustave Roussy, Cancer Campus, Grand Paris, with a registry enrolment figure of 162 participants, started 2025-11-17 and due to reach its primary completion in 2030-09. Interventions recorded: MaaT033 capsule; Cemiplimab; Cisplatin; Carboplatine; Pemetrexed (Alimta); Bevacizumab; Paclitaxel; gemcitabine; Docetaxel; Vinorelbine i.v. 25 mg/m²; Vinorelbine oral. Conditions listed: NSCLC (Advanced Non-small Cell Lung Cancer). Primary outcome: Disease Control Rate (DCR). Lung eligibility wording from the registry: "Histologically confirmed diagnosis of NSCLC (adenocarcinoma versus squamous cell carcinoma versus others)". Sites: France. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-25
- Also known as: IMMUNOLIFE2
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT07001618
- Phase: 2
- Setting: A Randomized Multicenter Phase II Trial Evaluating Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab (CB) Versus Best Investigator's Choice (BIC) in Resistance to PD-1/PD-L1 Blockade Due to Antibiotics (ATB) Uptake in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
- Sponsor: Gustave Roussy, Cancer Campus, Grand Paris
- Enrolled: 162

## Sources

- ClinicalTrials.gov NCT07001618: https://clinicaltrials.gov/study/NCT07001618

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- technologies: [Anti-angiogenic therapy](https://onco.cc/technologies/antiangiogenic/), [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Monoclonal antibodies](https://onco.cc/technologies/monoclonal-antibody/), [Platinum agents](https://onco.cc/technologies/platinum/)
- drugs: [Bevacizumab](https://onco.cc/drugs/bevacizumab/), [Cemiplimab](https://onco.cc/drugs/cemiplimab/), [Cisplatin](https://onco.cc/drugs/cisplatin/), [Docetaxel](https://onco.cc/drugs/docetaxel/), [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/), [Pemetrexed](https://onco.cc/drugs/pemetrexed/)
- companies: [MaaT Pharma](https://onco.cc/companies/maat-pharma/), [Regeneron](https://onco.cc/companies/regeneron/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07001618.json